The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
复制标题
DOI：
10.1034/j.1399-3062.2001.003002060.x
复制
发表时间：
2001-06-01
期刊：
影响因子：
--
通讯作者：
Alfieri, C
中科院分区：
文献类型：
--
作者：
Tanner, J E;Alfieri, C
移植患者在给予免疫抑制治疗后发生移植后淋巴组织增生性疾病（PTLD）的风险特别高。在许多情况下，PTLD病变表达EB病毒（EBV）潜伏和裂解基因以及宿主细胞因子水平升高。EB病毒，宿主细胞因子和T细胞，免疫抑制剂环孢素A，他克莫司，抗CD3抗体在这种疾病的机制和发病机制的潜在贡献的轮廓介绍和讨论。
Transplant patients are at particular risk for developing post-transplant lymphoproliferative disease (PTLD) following administration of immunosuppressive therapy. In many cases the PTLD lesions express Epstein-Barr virus (EBV) latent and lytic genes as well as elevated levels of host cytokines. An outline of the potential contributions of EBV, host cytokines and T cells, and the immunosuppressive cyclosporine A, tacrolimus, and anti-CD3 antibody in the mechanism and pathogenesis of this disease is presented and discussed.